Geode Capital Management LLC Has $307,000 Holdings in NextCure, Inc. (NASDAQ:NXTC)

Geode Capital Management LLC increased its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 14.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 223,741 shares of the company’s stock after purchasing an additional 27,812 shares during the period. Geode Capital Management LLC’s holdings in NextCure were worth $307,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Logos Global Management LP grew its stake in shares of NextCure by 29.9% during the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after purchasing an additional 575,000 shares during the period. Armistice Capital LLC acquired a new stake in shares of NextCure during the second quarter worth $57,000. Affinity Asset Advisors LLC lifted its holdings in NextCure by 24.2% during the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock worth $2,684,000 after acquiring an additional 328,918 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in NextCure by 15.4% during the second quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after acquiring an additional 61,744 shares in the last quarter. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Trading Down 2.6 %

NXTC stock opened at $0.78 on Tuesday. The business’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.34. The firm has a market cap of $21.79 million, a PE ratio of -0.37 and a beta of 0.67. NextCure, Inc. has a 1-year low of $0.76 and a 1-year high of $2.57.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their target price on NextCure from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, November 11th.

NextCure Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.